Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ligand Pharmaceuticals (LGND) Return on Invested Capital (2017 - 2025)

Historic Return on Invested Capital for Ligand Pharmaceuticals (LGND) over the last 15 years, with Q3 2025 value amounting to 0.02%.

  • Ligand Pharmaceuticals' Return on Invested Capital rose 300.0% to 0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.02%, marking a year-over-year increase of 300.0%. This contributed to the annual value of 0.05% for FY2024, which is 300.0% up from last year.
  • As of Q3 2025, Ligand Pharmaceuticals' Return on Invested Capital stood at 0.02%, which was up 300.0% from 0.04% recorded in Q2 2025.
  • Ligand Pharmaceuticals' 5-year Return on Invested Capital high stood at 0.14% for Q2 2021, and its period low was 0.06% during Q1 2025.
  • Over the past 5 years, Ligand Pharmaceuticals' median Return on Invested Capital value was 0.01% (recorded in 2023), while the average stood at 0.03%.
  • The largest annual percentage gain for Ligand Pharmaceuticals' Return on Invested Capital in the last 5 years was 1500bps (2021), contrasted with its biggest fall of -2300bps (2021).
  • Over the past 5 years, Ligand Pharmaceuticals' Return on Invested Capital (Quarter) stood at 0.13% in 2021, then crashed by -100bps to 0.0% in 2022, then surged by 2598bps to 0.01% in 2023, then surged by 194bps to 0.04% in 2024, then tumbled by -65bps to 0.02% in 2025.
  • Its last three reported values are 0.02% in Q3 2025, 0.04% for Q2 2025, and 0.06% during Q1 2025.